Establishment Labs (ESTA) vs Globus Medical (GMED)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Establishment Labs (ESTA) has outperformed Globus Medical (GMED) over the past year, gaining 53.7% versus a gain of 25.2%. Over five years, GMED leads with a -2.3% price change compared with -19.9% for ESTA. Globus Medical is the larger company by market cap ($10.02 billion vs $1.84 billion), about 5.5 times the size, while Establishment Labs is growing revenue faster (+27.1% vs +16.7%).
On valuation, Globus Medical trades at a lower forward P/E (13.8x vs 1027.8x for Establishment Labs). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus -24.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESTA | GMED |
|---|---|---|
| Share price | $61.67 | $74.65 |
| Market cap | $1.84B | $10.02B |
| 1-day change | +1.75% | +1.80% |
| YTD return | -15.38% | -14.50% |
| 1-year return | +53.71% | +25.23% |
| 5-year return | -19.91% | -2.33% |
| P/E ratio (TTM) | — | 19.14 |
| Forward P/E | — | 13.83 |
| EPS (TTM) | $-1.30 | $3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $211.08M | $2.94B |
| Revenue growth (YoY) | +27.14% | +16.65% |
| Net income (latest FY) | $-51.06M | $537.87M |
| Gross margin | 69.32% | 67.41% |
| Operating margin | -18.48% | 16.33% |
| Net margin | -24.19% | 18.30% |
| 52-week high | $97.59 | $101.40 |
| 52-week low | $38.55 | $56.66 |
| Distance from 52-week high | -36.81% | -26.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +66.11% | +35.19% |
| Average volume | 427.57K | 1.50M |
| Shares outstanding | 29.80M | 111.83M |
| Employees | 1,004 | 6,000 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Globus Medical is about 5.5 times larger than Establishment Labs by market value ($10.02B vs $1.84B).
- ESTA has outperformed GMED by 28.5 percentage points over the past year.
- Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -24.2 cents for Establishment Labs.
- Establishment Labs grew revenue faster in its latest fiscal year (+27.14% vs +16.65%).
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Health Care · Industrial Specialties · 1,004 employees
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
ESTA vs GMED FAQ
Which is bigger, Establishment Labs or Globus Medical?
Globus Medical (GMED) is larger, with a market capitalization of $10.02B compared with $1.84B for Establishment Labs (ESTA).
Which stock has performed better over the past year, ESTA or GMED?
ESTA returned +53.71% over the past 12 months, compared with +25.23% for GMED (price return, excluding dividends). Past performance does not predict future results.
Are Establishment Labs and Globus Medical in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Establishment Labs and Medical/Dental Instruments for Globus Medical.